June 05, 2026 01:48 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Was it directed by ruling ecosystem?': Congress questions LIC stake in Rajesh Exports under SEBI scanner | Boost for Congress! Vijay allots Tamil Nadu's lone Rajya Sabha seat to key ally | Fresh trouble for Mamata: Complaint filed over explosive Amit Shah claim in Osman Hadi case | 'Communication gap': Rajesh Exports rejects SEBI allegations, says revenues were not overstated | ₹15.2 lakh crore revenue questioned! SEBI action sends Rajesh Exports shares tumbling | 'If not now, when!': Sonam Wangchuk backs Cockroach Janta Party protest; spokespersons named ahead of founder Abhijeet Dipke's India return | Cabinet approves Rs. 10,000 crore support package to stabilise ATF prices for airlines | Delhi hotel inferno kills 21, many foreign nationals among victims | Mamata's TMC splits wide open as 58 MLAs back expelled Ritabrata as Bengal LoP | Cockroach Janta Party goes offline: Abhijeet Dipke set to return to Delhi, plans Jantar Mantar protest over exam lapses
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm